Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 17Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Mantle-Cell 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoblastic Lymphadenopathy 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1HIV Infections 1Cardiotoxicity 1

Interventions

Doxorubicin 17Echocardiography 14Exercise 9Cyclophosphamide 9Trastuzumab 8Dexrazoxane 8Electrocardiography 7Razoxane 6Carvedilol 6Vincristine 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cisplatin 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × VAP-cyclo protocol × Clear all
NCT00854568 2014-08-20

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Fudan University

Phase 3 Completed
398 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡